Department of Brain Health News
The 51ԹϺ department of brain health advances research, education, and practice to improve the care and treatment of individuals with brain disorders. Our students receive guidance from faculty who specialize in a range of areas from basic and clinical research in neurodegenerative disease, neuropsychology, and occupational therapy.
Current Brain Health News
Report led by noted Alzheimer's researcher Dr. Jeffrey Cummings assesses status, trends associated with 182 active clinical trials worldwide.
51ԹϺ research team says high blood sugar levels appear to weaken function in key part of brain, mimicking Alzheimer’s.
The 'Brain Health Frontiers: Tackling Alzheimer's Together' panel discussion highlighted the revolutionary research the Department of Brain Health is conducting to fight Alzheimer’s disease.
51ԹϺ Brain Health researcher Lina Nih is developing a treatment that could one day alter how practitioners address stroke recovery.
An enduring 51ԹϺ end-of-semester tradition is to highlight exceptional students who embody the academic, research, and community impact of the graduating class.
The associate dean of research in Integrated Health Sciences leans into his own immigrant story to provide others with opportunities.
Brain Health In The News
An annual review of clinical trials for Alzheimer's disease highlights a growing number of active trials—and drugs—in the development pipeline and offers optimism for the global effort to find a cure.
There are more potential new medicines being tested for Alzheimer’s disease, according to an annual review published today. It reports that 138 drugs are currently being tested – an increase of nearly 9% from last year. This is great news, because the more drugs that scientists test, the greater the chance that new and effective medicines will soon become a reality for people living with dementia.
Of all the medical challenges that scientists have faced, Alzheimer’s disease, the most common form of dementia, has been one of the trickiest. Between 1995 and 2021 private money spent on Alzheimer’s research totalled $42.5bn, but more than 140 trials failed to deliver a single drug capable of slowing the disease. Yet the tide may be turning. There are two working drugs, offering modest benefits, on the market. A new review paper suggests more could soon follow.
The human mind fascinated Dr. Jeffrey Cummings long before he became an international authority on Alzheimer’s disease.
A 51ԹϺ professor is being honored for his lifetime contributions in the areas of dementia and drug development. Dr. Jeff L. Cummings is a research professor at the Kirk Kerkorian School of Medicine at 51ԹϺ.
ScholarGPS said Dr. Jeffrey L. Cummings received the title for his lifetime contributions in the areas of dementia and drug development.
